| Project/Area Number |
23591963
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Yamaguchi University |
|---|
Principal Investigator |
SUZUKI Nobuaki 山口大学, 医学(系)研究科(研究院), 助教 (50526910)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
YOSHIMURA Kiyoshi 山口大学, 医学部附属病院, 助教 (30346564)
|
|---|
| Project Period (FY) |
2011 – 2013
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2012: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2011: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Keywords | HMGB1 / バイオマーカー / NKG2D / ULBP1 / B7-H3 / NKG2DL / Toll like receptor / 化学療法 / 免疫療法 / Toll like recepter |
|---|
| Research Abstract |
High mobility group box 1 (HMGB1) plays a role in many clinical conditions such as autoimmunity, acute ischemia-reperfusion injury, cardiovascular disease and cancer. HMGB1 is a nuclear protein and released from the apoptotic cells to activate cytotoxic T cells and antigen-presenting cells effectively. The aim of this study was to clarify HMGB1 is associated with recurrence or prognosis as a biomarker, and we performed immunohistochemistry of HMGB1 in resected specimen. We performed immunohistochemistry for 90 gastric cancer cases, 30 cases of colorectal cancer, and 10 cases as pancreatic cancer, the expression of HMGB1 in cancer tissues is a good prognostic factor in gastric cancer patients. B7-H3, NKG2D, NKG2DL are also stained, with a combination of expression of staining intensity, ULBP1/NKG2D interaction was suggested as good prognostic marker for the patients in gastric cancer.
|
